Cellyan Biotechnology Co., Ltd (HKPD) stock
Close on Nov 13, 2026Market cap $26.49MP/E –Yield –
Cellyan Biotechnology Co., Ltd saw revenue fall 33.9% to $13.43M over fiscal 2026. Free cash flow was -$787.07K, down 257.6% from a year earlier. At the latest close the market valued the company at $26.49M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2026, balances at Mar 31, 2026
Valuation
- Market cap
- $26.49M
- P/E ratio
- –
- Price to sales
- 1.97
- Price to book
- 2.75
- Dividend yield
- –
- Free cash flow yield
- -2.97%
Fundamentals
- Revenue
- $13.43M
- Net income
- -$1.14M
- EPS, diluted
- -$0.07
- Free cash flow
- -$787.07K
Trading
- Previous close
- $1.53
- Open
- $1.62
- Day's range
- $1.53 – $1.63
- Volume
- 7,975
- Average volume (20 days)
- 62,804
- 52-week range
- $0.10 – $29.00
- RSI (14 days)
- 51.7
- Volatility (1 year)
- 12244.9%
- Relative volume
- 0.00×
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 13, 2026. The S&P 500 is measured by the SPY fund.
| Period | HKPD | S&P 500 | Difference | HKPD per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | +1444.3% | -3.0% | +1447.4 pts | ||
| 3 months | -80.7% | -2.8% | −77.9 pts | ||
| Year to date | +96.5% | +11.5% | +85.0 pts | ||
| 1 year | -93.1% | +13.5% | −106.6 pts |
Four years at a glance
Fiscal years 2023 to 2026, USD
Revenue
Gross profit
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Cellyan Biotechnology filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
About Cellyan Biotechnology
Wholesale-Drugs, Proprietaries & Druggists' Sundries
Cellyan Biotechnology Co., Ltd. operates in the supply chain services and over-the-counter pharmaceutical sectors. Through its Supply Chain Services division, the company provides logistics solutions and cross-border procurement and distribution of over-the-counter pharmaceutical products. It engages with partners across the broader logistics industry, serving commercial merchants, consumers, and large logistics providers requiring specialized pharmaceutical distribution expertise.
Company profile, executives and historyCellyan Biotechnology stock: common questions
What is Cellyan Biotechnology's stock price?
HKPD closed at $1.62 on Nov 13, 2026, up 5.88% on the day. Over the past 52 weeks it traded between $0.10 and $29.00.
What is Cellyan Biotechnology's market cap?
Cellyan Biotechnology was worth $26.49M at the close on Nov 13, 2026: the share price times the diluted shares outstanding.
What is HKPD's P/E ratio?
Cellyan Biotechnology lost money over fiscal 2026 (diluted EPS -$0.07), so it has no meaningful P/E ratio.
How much revenue does Cellyan Biotechnology make?
Cellyan Biotechnology reported revenue of $13.43M for fiscal 2026, down 33.9% from a year earlier.
Does Cellyan Biotechnology pay a dividend?
No. Cellyan Biotechnology has not paid a cash dividend over the last twelve months.
How has HKPD stock performed over the past year?
Including dividends, HKPD returned -93.1% over the past year, against +13.5% for the S&P 500.
How many HKPD shares are sold short?
0M shares were sold short at the latest FINRA report, 0.57% of the float, or 1.0 days of average trading volume.
Who are Cellyan Biotechnology's competitors?
Companies most similar to Cellyan Biotechnology by business, industry and size include MEDS, COSM, STEK, BHATF, GVH.
See a number that looks wrong?